Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 313 clinical trials
Featured trial
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration

primary cancer
clear cell renal cell carcinoma
metastatic cancer
carcinoma
renal cell cancer
  • 210 views
  • 22 Dec, 2020
  • 1 location
Featured trial
AREN03B2: Study of Kidney Tumors in Young Patients

AREN03B2: Study of Kidney Tumors in Young Patients

  • 36 views
  • 08 Nov, 2020
  • 1 location
Featured trial
AREN03B2: Renal Tumors Classification, Biology, and Banking Study

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

  • 106 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …

metastatic renal cell carcinoma
systemic therapy
renal function tests
measurable disease
clear cell renal cell carcinoma
  • 2 views
  • 23 Nov, 2020
  • 3 locations
Featured trial
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …

tyrosine
systemic therapy
VEGFR2
nivolumab
carcinoma
  • 57 views
  • 15 Sep, 2020
  • 1 location
Featured trial
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 53 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 80 views
  • 23 Nov, 2020
  • 1 location
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

  • 0 views
  • 20 Jun, 2022
  • 1 location
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 …

  • 0 views
  • 17 Sep, 2023
  • 1 location
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer (PE-PE)

This is a phase II trial aiming at assessing the efficacy of pembrolizumab to delay tumor progression in patients with oligometastatic clear cell metastatic Renal Cell Carcinoma (mRCC). Eligible patients for this trial should have received previous surgery for primary tumor and have maximum of three metastases considered eligible for …

  • 0 views
  • 03 Sep, 2023
  • 1 location